Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC

Next Previous
Trial Profile

Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Carboplatin; Cisplatin; Docetaxel; Gemcitabine; Paclitaxel; Pemetrexed; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate 816
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 22 May 2025 According to Bristol Myers Squibb media release, data from this study will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held on Friday, May 30, 2025 in Chicago, Illinois.
  • 19 Feb 2025 According to a Bristol-Myers Squibb media release, The company will conduct an analysis of the updated data and plans to provide a comprehensive update on the data in a future peer reviewed setting.
  • 19 Feb 2025 Results presented in the Bristol-Myers Squibb media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top